Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts

Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts

Interleukin (IL-) 6 is a key factor in the inflammatory processes of rheumatoid arthritis. Several biologic agents target the IL-6 signaling pathway, including sarilumab, a monoclonal antibody that blocks the IL-6 receptor and inhibits IL-6-mediated cis- and trans-signaling. A careful analysis of th...

Full description

Bibliographic Details
Main Authors:	Annett Klinder, Janine Waletzko-Hellwig, Marie-Luise Sellin, Anika Seyfarth-Sehlke, Markus Wolfien, Franziska Prehn, Rainer Bader, Anika Jonitz-Heincke
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Series:	Pharmaceutics
Subjects:	Interleukin 6 sarilumab soluble IL-6 receptor antagonism human osteoblasts osteogenic differentiation
Online Access:	https://www.mdpi.com/1999-4923/14/7/1390

Similar Items

Sarilumab use in severe Coronavirus Disease 2019 pneumonia
by: Ahmed M.A. El Fattah Amer, et al.
Published: (2023-01-01)

New possibilities of drug therapy for rheumatoid arthritis: focus at sarilumab
by: D. E. Karateev, et al.
Published: (2019-11-01)

Inflammatory Response of Human Peripheral Blood Mononuclear Cells and Osteoblasts Incubated With Metallic and Ceramic Submicron Particles
by: Annett Klinder, et al.
Published: (2018-04-01)

Inhibitor of biological effects of interleukin-6 sarilumab in treatment of rheumatoid arthritis
by: D. E. Karateev, et al.
Published: (2019-12-01)

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
by: Andrea Marino, et al.
Published: (2022-05-01)

The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence
by: E. L. Nasonov, et al.
Published: (2019-11-01)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
by: Crotti C, et al.
Published: (2018-08-01)

Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
by: E. L. Nasonov, et al.
Published: (2019-05-01)

Effects of Build Orientation on Surface Morphology and Bone Cell Activity of Additively Manufactured Ti6Al4V Specimens
by: Volker Weißmann, et al.
Published: (2018-05-01)

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
by: Raimondo MG, et al.
Published: (2017-05-01)

Tolerability of Sarilumab – An anti-interleukin-6 receptor monoclonal antibody is controversial for the management of COVID-19
by: Justin Jacob Abraham, et al.
Published: (2021-01-01)

Polymyalgia Rheumatica Treated with Sarilumab
by: Anvitha Madhavaram, et al.
Published: (2023-12-01)

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
by: Luis Sainz, et al.
Published: (2023-11-01)

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
by: Wolfgang A. Schmidt, et al.
Published: (2023-10-01)

Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial
by: Rosario García-Vicuña, et al.
Published: (2022-02-01)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
by: Mark C. Genovese, et al.
Published: (2020-06-01)

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
by: Vibeke Strand, et al.
Published: (2020-10-01)

Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19
by: Tatyana S. Kruglova, et al.
Published: (2021-11-01)

A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages
by: Maaike C. Swets, et al.
Published: (2023-04-01)

Alternating Electric Fields Modify the Function of Human Osteoblasts Growing on and in the Surroundings of Titanium Electrodes
by: Franziska Sahm, et al.
Published: (2020-09-01)

The influence of metallic ions from CoCr28Mo6 on the osteogenic differentiation and cytokine release of human osteoblasts
by: Jonitz-Heincke A, et al.
Published: (2015-09-01)

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
by: Yoshiya Tanaka, et al.
Published: (2019-03-01)

Biomimetic Calcium Phosphate Coatings for Bioactivation of Titanium Implant Surfaces: Methodological Approach and In Vitro Evaluation of Biocompatibility
by: Thomas Kreller, et al.
Published: (2021-06-01)

Sarilumab use in severe SARS-CoV-2 pneumonia
by: Elisa Gremese, et al.
Published: (2020-10-01)

Devitalizing Effect of High Hydrostatic Pressure on Human Cells—Influence on Cell Death in Osteoblasts and Chondrocytes
by: Janine Waletzko, et al.
Published: (2020-05-01)

Characterization of the osteogenic differentiation capacity of human bone cells on hybrid β-TCP/ZrO2 structures
by: Lena-Christin Ingwersen, et al.
Published: (2024-02-01)

BMP-2 Long-Term Stimulation of Human Pre-Osteoblasts Induces Osteogenic Differentiation and Promotes Transdifferentiation and Bone Remodeling Processes
by: Lena-Christin Ingwersen, et al.
Published: (2022-03-01)

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
by: Su-Yeon Yu, et al.
Published: (2022-12-01)

Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison
by: Thomas Huizinga, et al.
Published: (2023-02-01)

Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)Research in context
by: Ilaria Mastrorosa, et al.
Published: (2023-03-01)

Isolation of Human Osteoblast Cells Capable for Mineralization and Synthetizing Bone-Related Proteins In Vitro from Adult Bone
by: Daria Kostina, et al.
Published: (2022-10-01)

Anti-IL6 Autoantibodies in an Infant With CRP-Less Septic Shock
by: Marketa Bloomfield, et al.
Published: (2019-11-01)

Establishment and Evaluation of an In Vitro System for Biophysical Stimulation of Human Osteoblasts
by: Martin Stephan, et al.
Published: (2020-08-01)

Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019
by: Qian Gao, et al.
Published: (2022-12-01)

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
by: Cem Gabay, et al.
Published: (2020-04-01)

Migration Capacity and Viability of Human Primary Osteoblasts in Synthetic Three-dimensional Bone Scaffolds Made of Tricalciumphosphate
by: Hermann Seitz, et al.
Published: (2011-07-01)

Osteogenic Response to Polysaccharide Nanogel Sheets of Human Fibroblasts After Conversion Into Functional Osteoblasts by Direct Phenotypic Cell Reprogramming
by: Kei Nakai, et al.
Published: (2021-09-01)

Effect of Cold Atmospheric Plasma (CAP) on Osteogenic Differentiation Potential of Human Osteoblasts
by: Benedikt Eggers, et al.
Published: (2022-02-01)

The effects of 6-gingerol on proliferation, differentiation, and maturation of osteoblast-like MG-63 cells
by: J.Z. Fan, et al.
Published: (2015-07-01)